Last edition
News about "MIZAR-003 Phase 2 Clinical Trial"
Innovent Announces NMPA Acceptance of New Indication Application of Sintilimab
Innovent’s sintilimab application for advanced melanoma is accepted by China’s NMPA, supported by results from the pivotal phase 2 MIZAR-003 clinical study.
MIZAR-003 Phase 2 Clinical Trial | 27/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members